Last reviewed · How we verify
CKD-330
CKD-330 is a novel therapeutic agent in phase 3 development by Chong Kun Dang Pharmaceutical with a mechanism not publicly disclosed in standard references.
At a glance
| Generic name | CKD-330 |
|---|---|
| Sponsor | Chong Kun Dang Pharmaceutical |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Limited public information is available regarding the specific molecular mechanism of CKD-330. As a phase 3 candidate from Chong Kun Dang, a South Korean pharmaceutical company, the drug is in late-stage clinical development, but detailed mechanistic data has not been widely published in accessible databases.
Approved indications
Common side effects
Key clinical trials
- A Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics of CKD-333 or Co-administration of CKD-333 and D085 in Healthy Volunteers (PHASE1)
- Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-333 Low Dose in Healthy Volunteers (PHASE1)
- Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics in Healthy Volunteers (PHASE1)
- Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of CKD-333 in Healthy Volunteers (PHASE1)
- Clinical Trial to Evaluate the Efficacy and Safety of CKD-333 Tablet (PHASE3)
- Compare the Pharmacokinetics and Safety of CKD-333 With Co-administration CKD-330 and D090 in Healthy Male Adults (PHASE1)
- Pharmacokinetics and Safety Profile of CKD-333 (PHASE1)
- Pharmacokinetic Drug-drug Interaction of CKD-330 and D086 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CKD-330 CI brief — competitive landscape report
- CKD-330 updates RSS · CI watch RSS
- Chong Kun Dang Pharmaceutical portfolio CI